Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2021

View Archived Issues

Triumvira initiates phase I/II trial of TAC-01-HER2 in relapsed or refractory solid tumors

First-in-human trial evaluates RPTR-168 in HPV-16 E6/E7-positive tumors and melanoma

AbCellera and Eli Lilly present second antibody to enter clinical development against COVID-19

First-in-human data for RZ-402 show potential for once-daily dosing

Vivace advances phase I trial of VT-3989 in solid tumors

Seqirus quadrivalent influenza vaccine Flucelvax noninferior to standard in children

Oral oncolytic reovirus RC-402 elicits potent immune responses against colon cancer

Novel GLUT5 inhibitor molecule to treat fructose-induced diseases

Study identifies four Alzheimer's subtypes

Silverback Therapeutics patents TGFBR1 inhibitors

Boswellic acid derivative inhibits Th17 cell differentiation by targeting eIF2alpha

Combination of pacritinib/sirolimus/low-dose tacrolimus for GvHD: preclinical and phase I results

Pipeline Therapeutics synthesizes muscarinic M1 receptor antagonists

BioCryst Pharmaceuticals patent details complement factor D inhibitors

Boehringer Ingelheim discovers TRPA1 antagonists

General Regeneratives patents IL-33 protein for cancer immunotherapy

FDA grants accelerated approval to Keytruda for first-line gastric or GEJ adenocarcinoma

Adagio initiates global phase II/III EVADE study of ADG-20 for the prevention of COVID-19

GB-1265: a galactin-3 inhibitor for corneal fibrosis

Revelation reports phase I data on REVTx-99

ADG-126, a novel cancer immunotherapy candidate with improved safety and efficacy

European Commission approves Xtandi for metastatic hormone-sensitive prostate cancer

Benlysta approved in E.U. for active lupus nephritis

Targeting RRM2 and mutant p53 as novel therapeutic strategy in TNBC

Moderna reports initial COVID-19 vaccine booster data with mRNA-1273 and mRNA-1273.351

Phase II trial evaluates Telomelysin, pembrolizumab and stereotactic radiation in head & neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...